AVENUE THERAPEUTICS, INC. Quarterly General and Administrative Expense in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Summary
Avenue Therapeutics, Inc. quarterly/annual General and Administrative Expense history and growth rate from Q1 2016 to Q3 2024.
  • Avenue Therapeutics, Inc. General and Administrative Expense for the quarter ending September 30, 2024 was $829K, a 28.6% decline year-over-year.
  • Avenue Therapeutics, Inc. General and Administrative Expense for the twelve months ending September 30, 2024 was $4.75M, a 26% decline year-over-year.
  • Avenue Therapeutics, Inc. annual General and Administrative Expense for 2023 was $4.18M, a 21.8% decline from 2022.
  • Avenue Therapeutics, Inc. annual General and Administrative Expense for 2022 was $5.35M, a 115% increase from 2021.
  • Avenue Therapeutics, Inc. annual General and Administrative Expense for 2021 was $2.48M, a 5.84% increase from 2020.
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Quarterly (USD)
General and Administrative Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $4.75M $829K -$332K -28.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $5.08M $1.46M +$566K +63.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 $4.51M $1.32M +$332K +33.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $4.18M $1.14M -$2.23M -66.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-18
Q3 2023 $6.41M $1.16M +$692K +148% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $5.72M $896K +$442K +97.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 $5.27M $984K -$71K -6.73% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $5.35M $3.37M +$2.84M +543% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-18
Q3 2022 $2.5M $469K -$125K -21% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $2.63M $454K -$169K -27.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $2.8M $1.06M +$312K +42% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $2.48M $524K +$9K +1.75% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $2.48M $594K +$23K +4.03% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $2.45M $623K -$61K -8.92% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $2.51M $743K +$166K +28.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $2.35M $515K -$104K -16.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-25
Q3 2020 $2.45M $571K -$46K -7.46% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $2.5M $684K -$32K -4.47% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $2.53M $577K -$542K -48.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $3.07M $619K -$768K -55.4% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 $3.84M $617K -$203K -24.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $4.04M $716K -$211K -22.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 $4.25M $1.12M +$133K +13.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $4.12M $1.39M +$283K +25.6% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 $3.84M $820K -$28K -3.3% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 $3.87M $927K -$370K -28.5% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 $4.24M $986K +$615K +166% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q4 2017 $3.62M $1.1M +$800K +263% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 $2.82M $848K +$648K +324% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 $2.17M $1.3M +$1.08M +498% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 $1.09M $371K +$95K +34.4% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 $997K $304K Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 $200K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $217K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
Q1 2016 $276K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.